Sierra Oncology Inc (SRRA) Stock Analyst Ratings
NASDAQ:SRRA - Nasdaq - US82640U4040 - Common Stock
ChartMill assigns a Buy % Consensus number of 76% to SRRA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 56.1. This target is 2.02% above the current price.
SRRA was analyzed by 10 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about SRRA.
In the previous month the buy percentage consensus was at a similar level.
SRRA was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-04-14 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-04-14 | Jefferies | Downgrade | Buy -> Hold |
| 2022-04-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-01-31 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-30 | Cantor Fitzgerald | Maintains | Overweight |
| 2021-11-05 | HC Wainwright & Co. | Maintains | Buy |
| 2021-09-27 | Cantor Fitzgerald | Initiate | Overweight |